Does low DHEA‑S after menopause lead to low free testosterone and reduced vitality?

Mechanistic pathways of postmenopausal hormone synthesis

After menopause, ovarian steroidogenesis sharply declines, making the peripheral conversion of adrenal precursors the primary source of estrogens and androgens. Circulating, biologically inactive dehydroepiandrosterone sulfate (DHEA-S) acts as a critical precursor reservoir. In target tissues—such as adipose, bone, skin, and the genitourinary tract—DHEA-S undergoes a localized, intracrine enzymatic cascade:

• Desulfation: Steroid sulfatase (STS) hydrolyzes circulating DHEA-S into active DHEA.
• Androgen conversion: Sequential metabolism by 3β-hydroxysteroid dehydrogenase (3β-HSD) and 17β-hydroxysteroid dehydrogenase (17β-HSD) converts DHEA into androstenedione and then testosterone.
• Estrogen conversion: Aromatase (CYP19A1) converts these downstream androgens into estrone and estradiol.

Because DHEA-S is the principal starting substrate, a decline in its levels directly limits the local precursor pool, resulting in a corresponding decrease in circulating free testosterone.

Clinical evidence and physical vitality

While the biochemical link between low DHEA-S and low free testosterone is well-established, the relationship between these hormones and subjective physical vitality is complex and only partially supported:

• Skeletal muscle correlation: Free testosterone levels correlate positively with skeletal muscle mass index in older women. A decline may contribute to sarcopenia, reduced physical strength, and perceived fatigue.
• Observational vs. clinical data: Although cohort studies link lower DHEA-S levels to reduced physical vigor and increased depressive symptoms, randomized controlled trials (RCTs) do not support a simple causal relationship.
• Therapeutic efficacy: RCTs of DHEA supplementation in postmenopausal women demonstrate no consistent, clinically meaningful improvements in energy, fatigue, or quality of life compared to placebo. Testosterone therapy remains primarily indicated for hypoactive sexual desire disorder, showing inconsistent benefits for broader vitality or fatigue.

Bottom line

• Postmenopause shifts hormone synthesis to peripheral tissues relying on adrenal DHEA-S; while low DHEA-S directly reduces downstream free testosterone substrate, restoring these hormones clinically does not reliably improve vitality, indicating that postmenopausal fatigue is multifactorial and not solely driven by androgen levels.